Associate Editor, Ophthalmology Times
Grant from the Optica Foundation fuels research to help detect undetectable glaucoma
The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.
Tarsus Pharmaceuticals announces topline results from Ersa Phase 2a trial evaluating lotilaner ophthalmic solution, 0.25%.
TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and s being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
CDR-Life Inc doses first patient in phase 1 trial of BI 771716
The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.
Kubota Vision announces multiple partnerships around its eyeMO OCT device
The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.
OKYO Pharma announces final patient in OK-101 trial for dry eye disease completed dosing study
The company says top-line efficacy and safety data is on track for release in December of 2023.
Sonepur District Headquarters Hospital ophthalmologist caught taking bribes to conduct surgery
Sanjib Kumar Kar, MBBS, MD, was caught taking a bribe of ₹5,500 (~$65 USD) from a complainant to conduct surgery on his uncle.
Enzene Biosciences launches biosimilar to ranibizumab for treatment of neovascular age-related macular degeneration (AMD)
The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).
Navigating disability insurance for ophthalmologists: Lessons learned
Physician details her journey from sustaining career-ending injury to insurance advocate.
Rising pollution levels in Delhi trigger 40% surge in eye problems
Air quality across Delhi has been in the “very poor” category, with AQI ranging from 350 to a severe rating of 450.
$2.9 Million boost for Australia's first saliva-based glaucoma genetic test
Flinders University Ophthalmologists have devised a novel glaucoma polygenic risk score (PRS) that identifies those at high risk of losing their sight and prioritizes their treatment.
Orbis International online course equips healthcare workers to identify glaucoma signs
A study of the course was conducted in Vietnam, and showed participant scores doubled following the online course, to a level like local ophthalmologists.
FDA issues warning letter to Amazon for selling unapproved eye care products
This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.
Prevent Blindness launches fourth annual Thyroid Eye Disease Week
The week focuses on bringing awareness to TED through emphasis on mental health and art therapy solutions.
A free ophthalmic surgery campaign in Brazil leads to numerous infections and enucleations
Nearly 75% of patients suffered eye infections following the event.
AAO 2023: Paul Runge and his ROP treatments in the Ukraine
Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.
Amydis unveils Phase 2 clinical trial for Glaucoma detection technology
AMDX-2011P aims to revolutionize glaucoma detection with micron-level amyloid beta tracking.
Bausch + Lomb receives CPT Category 1 Code for triamcinolone acetonide injectable suspension (XIPERE) from American Medical Association
XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.
Amgen confirms FDA accepted Biologics License Application for ABP 938
ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).
Kodiak Sciences reboots tarcocimab tedromer development program after strong positive results in Phase 3 GLOW study
Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint.
AAO 2023: Phase III CHAMP and more trials pioneering myopia management in children
Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.
AAO 2023: IRIS Registry set to present data from 20 big data studies
Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.
AAO 2023: FundamentalVR and AAO team up for pediatric ophthalmic training VR program
The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.
PolyActiva reports promising results from Phase 2a clinical study of biodegradable implant for treatment of mild to moderate glaucoma
Eight patients were able to receive a second implant at 21 weeks, with no product related adverse effects.
STAAR Surgical celebrates 30th anniversary of Implantable Collamer Lens (ICL).
EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.
Aldeyra Therapeutics faces stock plunge and potential FDA setback for reproxalap approval
Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.
AffaMed Technologies secures exclusive rights for revolutionary EVOLUX® IOL in Greater China market
AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.
Positive phase 3 DIAMOND trial results for OCS-01 in DME unveiled at EURETINA congress
The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.
October 14, 2023 annular eclipse set to cast shadow over western US
Prevent Blindness emphasizes the importance of proper eye protection, as exposure to the sun during an eclipse can cause "eclipse blindness" or retinal burns, which can be temporary or permanent.
New study reveals improved eye health could boost US economy by $50.4 billion annually
A groundbreaking study conducted by the International Agency for the Prevention of Blindness (IAPB) and Kevin Frick, PhD, from Johns Hopkins University reveals that prioritizing better eye health could inject a staggering $50.4 billion annually into the US economy.
World Sight Day: HCP Cureblindness brings attention to avoidable vision loss globally
Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.
2 Commerce Drive Cranbury, NJ 08512